Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 73

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 73
---
 less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards. |

| • |     | Under our amended and restated memorandum and articles of association, investors do not have the same rights 
 with respect to shareholder meetings and voting that shareholders of some U.S. corporations have.            |

| • |     | We may lose our foreign private issuer status in the future, which could result in significant additional 
 costs and expenses.                                                                                       |

| • |     | Fluctuations in currency exchange rates may have a material adverse effect on our results of operations and 
 the value of any investment in our Ordinary Shares.                                                         |

| • |     | Investors may not receive distributions on our Ordinary Shares or any value for them if such distribution is                                   
 illegal or impractical or if any required government approval cannot be obtained in order to make such distribution available to any investor. |

| • |     | Investors’ right to participate in any future rights offerings may be limited, which may cause dilution 
 to holdings in our Ordinary Shares.                                                                     |

| • |     | Investors may face difficulties in protecting the interests of investors, and the ability to protect the      
 rights of investors through U.S. courts may be limited, because we are incorporated under Cayman Islands law. |

| • |     | We may experience material weaknesses in our internal control over financial reporting in the future. If so,                                                                                                                                       
 or if we otherwise fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely consolidated financial statements could be impaired, investors may lose confidence in our financial 
 reporting and the trading price of our Ordinary Shares may decline.                                                                                                                                                                                |

| • |     | Our amended and restated memorandum and articles of association contain anti-takeover provisions that could                                               
 discourage a third party from acquiring us, which could limit our shareholders’ opportunity to sell their shares, including Ordinary Shares at a premium. |

| • |     | We could be subject to securities class action litigation. |

10

| • |     | If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable 
 research about our business, the market price for our Ordinary Shares and trading volume could decline.     |

| • |     | The increasing use of social media platforms presents new risks and challenges. |

11

THE OFFERING

| Ordinary Shares offered by us in the offering | Ordinary Shares having an aggregate offering price of up to |

$150,000,000.

| Manner of Offering